313 related articles for article (PubMed ID: 28603075)
1. Prognostic significance of SOCS3 and its biological function in colorectal cancer.
Chu Q; Shen D; He L; Wang H; Liu C; Zhang W
Gene; 2017 Sep; 627():114-122. PubMed ID: 28603075
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasis.
Huang L; Hu B; Ni J; Wu J; Jiang W; Chen C; Yang L; Zeng Y; Wan R; Hu G; Wang X
J Exp Clin Cancer Res; 2016 Feb; 35():27. PubMed ID: 26847351
[TBL] [Abstract][Full Text] [Related]
3. Activation of the JAK-STAT3 pathway is associated with the growth of colorectal carcinoma cells.
Wei X; Wang G; Li W; Hu X; Huang Q; Xu K; Lou W; Wu J; Liang C; Lou Q; Qian C; Liu L
Oncol Rep; 2014 Jan; 31(1):335-41. PubMed ID: 24253664
[TBL] [Abstract][Full Text] [Related]
4. Identification of NCK1 as a novel downstream effector of STAT3 in colorectal cancer metastasis and angiogenesis.
Zhang F; Lu YX; Chen Q; Zou HM; Zhang JM; Hu YH; Li XM; Zhang WJ; Zhang W; Lin C; Li XN
Cell Signal; 2017 Aug; 36():67-78. PubMed ID: 28455144
[TBL] [Abstract][Full Text] [Related]
5. Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells.
Xiong H; Du W; Zhang YJ; Hong J; Su WY; Tang JT; Wang YC; Lu R; Fang JY
Mol Carcinog; 2012 Feb; 51(2):174-84. PubMed ID: 21520296
[TBL] [Abstract][Full Text] [Related]
6. Colorectal cancer cell-derived extracellular vesicles transfer miR-221-3p to promote endothelial cell angiogenesis via targeting suppressor of cytokine signaling 3.
Dokhanchi M; Pakravan K; Zareian S; Hussen BM; Farid M; Razmara E; Mossahebi-Mohammadi M; Cho WC; Babashah S
Life Sci; 2021 Nov; 285():119937. PubMed ID: 34508764
[TBL] [Abstract][Full Text] [Related]
7. IL-23 selectively promotes the metastasis of colorectal carcinoma cells with impaired Socs3 expression via the STAT5 pathway.
Zhang L; Li J; Li L; Zhang J; Wang X; Yang C; Li Y; Lan F; Lin P
Carcinogenesis; 2014 Jun; 35(6):1330-40. PubMed ID: 24464786
[TBL] [Abstract][Full Text] [Related]
8. Pien Tze Huang suppresses IL-6-inducible STAT3 activation in human colon carcinoma cells through induction of SOCS3.
Shen A; Chen Y; Hong F; Lin J; Wei L; Hong Z; Sferra TJ; Peng J
Oncol Rep; 2012 Dec; 28(6):2125-30. PubMed ID: 23027374
[TBL] [Abstract][Full Text] [Related]
9. Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer.
Shang AQ; Wu J; Bi F; Zhang YJ; Xu LR; Li LL; Chen FF; Wang WW; Zhu JJ; Liu YY
Cancer Biol Ther; 2017 May; 18(5):314-322. PubMed ID: 28448787
[TBL] [Abstract][Full Text] [Related]
10. OVOL2, an Inhibitor of WNT Signaling, Reduces Invasive Activities of Human and Mouse Cancer Cells and Is Down-regulated in Human Colorectal Tumors.
Ye GD; Sun GB; Jiao P; Chen C; Liu QF; Huang XL; Zhang R; Cai WY; Li SN; Wu JF; Liu YJ; Wu RS; Xie YY; Chan EC; Liou YC; Li BA
Gastroenterology; 2016 Mar; 150(3):659-671.e16. PubMed ID: 26619963
[TBL] [Abstract][Full Text] [Related]
11. MiR-340 affects gastric cancer cell proliferation, cycle, and apoptosis through regulating SOCS3/JAK-STAT signaling pathway.
Xiao C; Hong H; Yu H; Yuan J; Guo C; Cao H; Li W
Immunopharmacol Immunotoxicol; 2018 Aug; 40(4):278-283. PubMed ID: 29658372
[TBL] [Abstract][Full Text] [Related]
12. Human epidermal growth factor receptor 2 expressions and Janus-activated kinase/signal transducer and activator of transcription 3-suppressor of cytokine signaling 3 pathway may be associated with clinicopathological features and prognosis of gastric cancer.
Xu W; Fu J; Wu H; Sun W
J Cancer Res Ther; 2018 Jun; 14(Supplement):S311-S318. PubMed ID: 29970682
[TBL] [Abstract][Full Text] [Related]
13. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis.
Li Y; de Haar C; Chen M; Deuring J; Gerrits MM; Smits R; Xia B; Kuipers EJ; van der Woude CJ
Gut; 2010 Feb; 59(2):227-35. PubMed ID: 19926618
[TBL] [Abstract][Full Text] [Related]
14. SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway.
Chen M; Zeng J; Chen S; Li J; Wu H; Dong X; Lei Y; Zhi X; Yao L
Aging (Albany NY); 2020 Jun; 12(11):10896-10911. PubMed ID: 32516133
[TBL] [Abstract][Full Text] [Related]
15. The roles of SOCS3 and STAT3 in bacterial infection and inflammatory diseases.
Gao Y; Zhao H; Wang P; Wang J; Zou L
Scand J Immunol; 2018 Dec; 88(6):e12727. PubMed ID: 30341772
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in human cutaneous melanoma.
Wu ZS; Cheng XW; Wang XN; Song NJ
Melanoma Res; 2011 Dec; 21(6):483-90. PubMed ID: 21876460
[TBL] [Abstract][Full Text] [Related]
17. THAP9-AS1 Promotes Tumorigenesis and Reduces ROS Generation through the JAK2/STAT3 Signaling Pathway by Increasing SOCS3 Promoter Methylation in Osteosarcoma.
Yang S; Wang B; Liu C; Wang Q; Wang R; Su W; Zhu Y; Li M; Guo Z; Wu X; Chen F
Oxid Med Cell Longev; 2021; 2021():5620475. PubMed ID: 34691358
[TBL] [Abstract][Full Text] [Related]
18. Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression.
Oguro T; Ishibashi K; Sugino T; Hashimoto K; Tomita S; Takahashi N; Yanagida T; Haga N; Aikawa K; Suzutani T; Yamaguchi O; Kojima Y
Eur J Cancer; 2013 May; 49(7):1715-24. PubMed ID: 23274199
[TBL] [Abstract][Full Text] [Related]
19. SHP2, SOCS3 and PIAS3 Expression Patterns in Medulloblastomas: Relevance to STAT3 Activation and Resveratrol-Suppressed STAT3 Signaling.
Li C; Li H; Zhang P; Yu LJ; Huang TM; Song X; Kong QY; Dong JL; Li PN; Liu J
Nutrients; 2016 Dec; 9(1):. PubMed ID: 28035977
[TBL] [Abstract][Full Text] [Related]
20. SOCS3 inhibits the pathological effects of IL-22 in non-melanoma skin tumor-derived keratinocytes.
Madonna S; Scarponi C; Morelli M; Sestito R; Scognamiglio PL; Marasco D; Albanesi C
Oncotarget; 2017 Apr; 8(15):24652-24667. PubMed ID: 28445952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
